Literature DB >> 20049503

Determinants of health care costs of HIV-positive patients in the Canary Islands, Spain.

Juan Oliva-Moreno1, Julio López-Bastida, Pedro Serrano-Aguilar, Lilisbeth Perestelo-Pérez.   

Abstract

The aims of this study were to estimate medical expenditures on human immunodeficiency virus (HIV) treatment and to identify significant associated variables. We performed a retrospective multi-centre study in the Canary Islands using a sample of 569 patients recruited at outpatient visits. The study examined demographic and clinical variables, health-related quality of life (HRQOL), and health care resources. Clinical data was obtained from medical records and patient interviews. Several empirical models for identifying the relationship between health care costs and independent variables were developed. The greatest expense came from pharmaceutical expenditure (82.1% of direct costs), while hospital costs only represented 4.6% of total expenditure. The data showed a statistically significant association between health care costs and the CD4 count of the previous year. HRQOL was also a significant variable. Therefore, CD4 cell count can be used to predict health care costs in patients. Policymakers could use this information to help guide their decisions in allocating limited health care resources to HIV treatments.

Entities:  

Mesh:

Year:  2010        PMID: 20049503     DOI: 10.1007/s10198-009-0212-z

Source DB:  PubMed          Journal:  Eur J Health Econ        ISSN: 1618-7598


  43 in total

1.  Subjective state of health and survival in elderly adults.

Authors:  G Kaplan; V Barell; A Lusky
Journal:  J Gerontol       Date:  1988-07

Review 2.  The direct costs of HIV/AIDS care.

Authors:  Adrian R Levy; Douglas James; Karissa M Johnston; Robert S Hogg; P Richard Harrigan; Brian P Harrigan; Boris Sobolev; Julio S Montaner
Journal:  Lancet Infect Dis       Date:  2006-03       Impact factor: 25.071

3.  Using multidimensional health measures in older persons to identify risk of hospitalization and skilled nursing placement.

Authors:  A L Siu; D B Reuben; J G Ouslander; D Osterweil
Journal:  Qual Life Res       Date:  1993-08       Impact factor: 4.147

Review 4.  The cost of HIV treatment and care. A global review.

Authors:  E J Beck; A H Miners; K Tolley
Journal:  Pharmacoeconomics       Date:  2001-01       Impact factor: 4.981

5.  [Trends in the number of human immunodeficiency virus infected persons and AIDS cases in Spain: 1980-1998].

Authors:  J Castilla; L de la Fuente
Journal:  Med Clin (Barc)       Date:  2000-06-17       Impact factor: 1.725

6.  Economic evaluation of HIV treatments: the I.CO.N.A. cohort study.

Authors:  Monica Merito; Andrea Bonaccorsi; Fabio Pammolli; Massimo Riccaboni; Gianluca Baio; Claudio Arici; Antonella D'Arminio Monforte; Patrizio Pezzotti; Dario Corsini; Andrea Tramarin; Roberto Cauda; Vincenzo Colangeli; Giuseppe Pastore
Journal:  Health Policy       Date:  2005-11       Impact factor: 2.980

7.  A multicentre study of patient survival, disability, quality of life and cost of care: among patients with AIDS in northern Italy.

Authors:  Andrea Tramarin; Stefano Campostrini; Maarten J Postma; Guido Calleri; Keith Tolley; Nicoletta Parise; Fausto de Lalla
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

8.  The changing direct costs of medical care for patients with HIV/AIDS, 1995-2001.

Authors:  Hartmut B Krentz; M Christopher Auld; M John Gill
Journal:  CMAJ       Date:  2003-07-22       Impact factor: 8.262

9.  The high cost of medical care for patients who present late (CD4 <200 cells/microL) with HIV infection.

Authors:  H B Krentz; M C Auld; M J Gill
Journal:  HIV Med       Date:  2004-03       Impact factor: 3.180

10.  Predictors of employment of men with HIV/AIDS: a longitudinal study.

Authors:  Judith G Rabkin; Martin McElhiney; Stephen J Ferrando; Wilfred Van Gorp; Shu Hsing Lin
Journal:  Psychosom Med       Date:  2004 Jan-Feb       Impact factor: 4.312

View more
  4 in total

1.  Cost of HIV and determinants of health care costs in HIV-positive patients in Germany: results of the DAGNÄ K3A Study.

Authors:  Sarah Mostardt; Nikola Hanhoff; Jürgen Wasem; Armin Goetzenich; Knud Schewe; Eva Wolf; Christoph Mayr; Hans Jaeger; Holger Pfaff; Stephan Dupke; Anja Neumann
Journal:  Eur J Health Econ       Date:  2012-09-19

2.  The determinants of HIV treatment costs in resource limited settings.

Authors:  Nicolas A Menzies; Andres A Berruti; John M Blandford
Journal:  PLoS One       Date:  2012-11-07       Impact factor: 3.240

3.  Cost-effectiveness analysis of antiretroviral therapy in a cohort of HIV-infected patients starting first-line highly active antiretroviral therapy during 6 years of observation.

Authors:  Franco Maggiolo; Giorgio L Colombo; Sergio Di Matteo; Giacomo M Bruno; Noemi Astuti; Elisa Di Filippo; Giulia Masini; Claudia Bernardini
Journal:  Patient Relat Outcome Meas       Date:  2015-02-17

4.  Cost of HAART in Italy: multicentric evaluation and determinants from a large HIV outpatient cohort.

Authors:  Monica Tontodonati; Giovanni Cenderello; Benedetto Maurizio Celesia; Michele Trezzi; Tamara Ursini; Andrea Costantini; Domenico Marra; Ennio Polilli; Corrado Catalani; Luca Butini; Federica Sozio; Elena Mazzotta; Antonina Sciacca; Giuliano Rizzardini; Lamberto Manzoli; Alessandro Cozzi-Lepri; Giustino Parruti
Journal:  Clinicoecon Outcomes Res       Date:  2014-12-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.